JP7659905B2 - Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト - Google Patents

Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト Download PDF

Info

Publication number
JP7659905B2
JP7659905B2 JP2022502530A JP2022502530A JP7659905B2 JP 7659905 B2 JP7659905 B2 JP 7659905B2 JP 2022502530 A JP2022502530 A JP 2022502530A JP 2022502530 A JP2022502530 A JP 2022502530A JP 7659905 B2 JP7659905 B2 JP 7659905B2
Authority
JP
Japan
Prior art keywords
nmdar
autoantibodies
protein
construct
glun1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540913A (ja
JP2022540913A5 (https=
Inventor
コルナウ，ハンス－クリスチャン
プルス，ハーラル
カーティス ガーナー，クレイグ
フレイ，タニタ
Original Assignee
ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） filed Critical ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー）
Publication of JP2022540913A publication Critical patent/JP2022540913A/ja
Publication of JP2022540913A5 publication Critical patent/JP2022540913A5/ja
Priority to JP2025049513A priority Critical patent/JP2025094198A/ja
Application granted granted Critical
Publication of JP7659905B2 publication Critical patent/JP7659905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022502530A 2019-07-16 2020-07-02 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト Active JP7659905B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025049513A JP2025094198A (ja) 2019-07-16 2025-03-25 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19186524.5 2019-07-16
EP19186524 2019-07-16
LU101308 2019-07-18
LULU101308 2019-07-18
PCT/EP2020/068732 WO2021008890A1 (en) 2019-07-16 2020-07-02 Nmda receptor constructs to detect and isolate nmdar autoantibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025049513A Division JP2025094198A (ja) 2019-07-16 2025-03-25 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Publications (3)

Publication Number Publication Date
JP2022540913A JP2022540913A (ja) 2022-09-20
JP2022540913A5 JP2022540913A5 (https=) 2023-06-27
JP7659905B2 true JP7659905B2 (ja) 2025-04-10

Family

ID=71143759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502530A Active JP7659905B2 (ja) 2019-07-16 2020-07-02 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト
JP2025049513A Pending JP2025094198A (ja) 2019-07-16 2025-03-25 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025049513A Pending JP2025094198A (ja) 2019-07-16 2025-03-25 Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Country Status (6)

Country Link
US (1) US20230280340A1 (https=)
EP (1) EP3999850A1 (https=)
JP (2) JP7659905B2 (https=)
CN (1) CN114144427A (https=)
CA (1) CA3144900A1 (https=)
WO (1) WO2021008890A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025094198A (ja) * 2019-07-16 2025-06-24 ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
CN114957446B (zh) * 2022-05-31 2023-09-15 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
CN114891091B (zh) * 2022-06-13 2024-04-26 四川携光生物技术有限公司 一种抗nmdar脑炎重组抗原及应用
JPWO2024075803A1 (https=) * 2022-10-06 2024-04-11
CN116253790A (zh) * 2022-12-13 2023-06-13 迪亚莱博（张家港）生物科技有限公司 一种用于抗nmdar抗体检测的nmdar重组蛋白及其制备方法及其应用
CN116440950B (zh) * 2023-02-24 2023-09-12 华东理工大学 一种催化剂及其制备方法和应用
AU2024242885A1 (en) * 2023-03-30 2025-09-11 Arialys Therapeutics, Inc. Detection of autoantibodies against nr1
AU2024315618A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
CN118566499B (zh) * 2024-08-02 2024-10-08 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂
CN118937669B (zh) * 2024-10-11 2025-02-18 杭州臻源生物医药科技有限公司 双色荧光检测抗nmdar抗体用固定试剂、方法及应用
CN120721960B (zh) * 2025-08-19 2025-11-21 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096331A1 (en) 2001-06-27 2003-05-22 Dambinova Svetlana A. Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
US20090155261A1 (en) 2006-08-15 2009-06-18 Josep Dalmau Methods and compositions for treatment and diagnosis of encephalitis or epilepsy
JP2009541274A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770460B1 (en) * 1998-01-29 2004-08-03 Wallac Oy Fusion protein and its use in an immunoassay for the simultaneous detection of autoantibodies related to insulin-dependent diabetes mellitus
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
DE102010053432A1 (de) * 2010-12-06 2012-06-06 Euroimmun Medizinische Labordiagnostika Ag Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
KR20160135749A (ko) * 2014-03-18 2016-11-28 샌포드 헬스 유방암 검출용 시약 및 검출 방법
GB201409234D0 (en) * 2014-05-23 2014-07-09 Isis Innovation Method
EP3999850A1 (en) * 2019-07-16 2022-05-25 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Nmda receptor constructs to detect and isolate nmdar autoantibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096331A1 (en) 2001-06-27 2003-05-22 Dambinova Svetlana A. Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
JP2009541274A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
US20090155261A1 (en) 2006-08-15 2009-06-18 Josep Dalmau Methods and compositions for treatment and diagnosis of encephalitis or epilepsy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biological Psychiatry，2017年，Vol.82, No.10，p.766-772

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025094198A (ja) * 2019-07-16 2025-06-24 ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト

Also Published As

Publication number Publication date
EP3999850A1 (en) 2022-05-25
US20230280340A1 (en) 2023-09-07
JP2025094198A (ja) 2025-06-24
JP2022540913A (ja) 2022-09-20
CA3144900A1 (en) 2021-01-21
CN114144427A (zh) 2022-03-04
WO2021008890A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7659905B2 (ja) Ｎｍｄａｒ自己抗体を検出及び単離するためのｎｍｄａ受容体コンストラクト
ES2268786T3 (es) Ensayo de union usando antigenos embebidos en termoplastico.
CN101925819B (zh) 结核分歧杆菌复合群的免疫检出方法
CA2781117C (en) Peptides, devices, and methods for the detection of ehrlichia antibodies
Yamazaki et al. Cell membrane array fabrication and assay technology
KR20140091735A (ko) 라임 질환 항체의 검출을 위한 펩타이드 및 방법
KR20070117533A (ko) 프리온 단백질의 결합 물질 및 사용 방법
KR20120096932A (ko) 라임병 항체의 검출을 위한 펩티드 및 방법
EP2952898A1 (en) Diagnosis of a neurological disease
JP7011600B2 (ja) 被験体の免疫状態をモニタリングするための改善された方法
EP3897696A1 (en) Extracorporeal devices for methods for treating diseases associated with anti-neutrophil cytoplasmic antibodies
JP5746328B2 (ja) ヒト睾丸および副睾丸で発現される３０５種類の生殖関連精子局在タンパク質の検出方法
US4322274A (en) Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
Seo et al. Sandwich antibody arrays using recombinant antibody-binding protein L
CA2597136A1 (en) Compositions and methods for purifying and crystallizing molecules of interest
BR102021022687A2 (pt) Método e reagentes para diagnosticar nefropatia membranosa
Kleine et al. Interactions of antibodies to the gram-negative gastric bacterium helicobacter pylori with the synaptic calcium sensor synaptotagmin 5, correlate to impaired vesicle recycling in SiMa human neuroblastoma cells
CN114137231B (zh) 一种血型不规则抗体的检测试剂盒及其应用
JP6749221B2 (ja) 疥癬の検査方法、並びにそれに用いる薬剤及びデバイス
FI104219B (fi) Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi
KR102301987B1 (ko) 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
Perosa et al. Absence of streptococcal protein G (PG)‐specific determinant in the Fab region of human IgG2
Molatseli Anti-mycolic acid gallibodies as labelling tools in tuberculosis-related biological samples
WO2026093984A1 (en) Method and kit for detecting antibodies against podocin, kirrel1, and ptpro for kidney disease diagnosis
EP3872492A1 (en) Identifying borna disease virus (bodv) infection through detection of antibodies against the bodv glycoprotein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250325

R150 Certificate of patent or registration of utility model

Ref document number: 7659905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150